Pharmacogenetics specialis Lab21 has appointed Stephen Mathews to head up its pharmaceutical and biotech business development team
Welcoming Stephen Mathews at the company's Cambridge UK laboratories, scientific operations director Stan Tyms said: "Stephen is a skilled manager with extensive experience in scientific and technical markets.
"He joins Lab21 at a stage when our testing services for pharmaceutical research and clinical trials are second to none".
Founded in April 2005, Lab21 provides technically advanced laboratory services that it says deliver real clinical insight.
The company's high level of experience and know-how is coupled with a rapidly growing portfolio of molecular and viral diagnostics, such as viral load and resistance profiling, plus pharmacogenetic (PGx) and patient-profiling tests such as Cytochrome P450.
All are based on cutting edge technology, it says.
This unique combination adds value to early stage drug development, clinical trials and regulatory processes in the pharmaceutical and biotech industries.
It can also be applied directly to clinicians or healthcare providers to help in the treatment and monitoring of patients.
